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Abstract: Cardiovascular disease is the leading cause of the poor long-term survival of patients 
with chronic kidney disease (CKD). Anemia complicating CKD not only impairs patients’ quality 
of life, but is also an independent risk factor for adverse cardiovascular outcomes. The avail-
ability of recombinant human erythropoietin (rHuEPO) has greatly changed the management 
of anemia in CKD patients. Besides improving hemoglobin levels, rHuEPO therapy has been 
demonstrated to signiﬁ  cantly improve quality of life and decrease morbidity and mortality in 
patients with CKD. Epoetin beta, together with epoetin alfa and darbepoetin alfa, is one of the 
erythropoiesis-stimulating agents now available on the market. Different studies have shown 
that epoetin beta once-weekly administration to hemodialysis patients is as effective as three-
times-weekly administration in maintaining hemoglobin levels at equivalent weekly doses. 
This raises the possibility of reducing the frequency of administration of rHuEPO therapy, thus 
increasing the alternatives available for tailoring anemia therapy to patients needs, and at the 
same time reducing nursing times and treatment costs. This is expected to potentially enhance 
patient compliance, thus helping more patients achieve their target hemoglobin levels.
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Introduction
Chronic kidney disease (CKD) patients are affected by considerable cardiovascular 
morbidity and mortality. Cardiovascular complications are the main cause of death 
among patients on dialysis (Locatelli et al 2000; Collins et al 2005) and cardiovascu-
lar mortality rates are approximately 10–20 times greater than those observed in the 
general population (Foley et al 1998). The burden of cardiovascular disease is huge 
also during the conservative phase of CKD: the number of CKD patients progress-
ing towards the need for renal replacement treatment is indeed much lower than the 
number of those dying, mainly due to cardiovascular disease itself, before reaching the 
point of end-stage renal disease (ESRD) (Keith et al 2004; Foley et al 2005). In this 
context, anemia has gained increasing attention, based on its well documented role as a 
speciﬁ  cally CKD-related cardiovascular risk factor. Anemia is a frequent complication 
of patients with CKD and is mainly characterized by a reduced ability of the damaged 
kidney to produce erythropoietin (EPO), the hormone involved in proliferation and 
maturation of red blood cells in the bone marrow. Hb levels can start to decrease even 
at an early stage of CKD (Levin 2001; Astor et al 2002). It has been found that among 
patients with a creatinine clearance of more than 50 mL/min (early kidney disease), 
25% have already developed anemia (deﬁ  ned as Hb <13 mg/dL), and the prevalence of 
anemia increases dramatically as creatinine clearance further decreases (Levin 2001). 
Anemia is often more severe and occurs at an earlier stage in patients with diabetic Therapeutics and Clinical Risk Management 2007:3(3) 434
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nephropathy in comparison with patients with CKD of other 
causes (Thomas and Rampersad 2004).
Association of renal anemia with 
cardiovascular morbidity and 
mortality
Several reports have shown an association between of 
anemia and the development of cardiovascular complica-
tions in patients with CKD (Harnet et al 1995; Parfrey et 
al 1996; Levin 2002). It is thought that these associations 
are mainly due to the impact of chronic anemia on cardiac 
function, by means of vasodilation, cardiac dilation, and 
increased cardiac output, ﬁ  nally leading to left ventricular 
dilation and compensatory hypertrophy (Anand et al 1993). 
The association between anemia and cardiovascular disease 
can also be explained by the reduction in oxygen delivery 
throughout the body, whereas it has been suggested that 
anemia, congestive heart failure, and CKD are all inter-
related, each causing the other to worsen, resulting in a 
vicious cycle of disease progression (Silverberg 2003). 
Complications that have been most consistently associ-
ated with anemia are indeed left ventricular hypertrophy, 
congestive heart failure, and ischemic heart disease (Foley 
et al 1996; Levin 2002). 
Anemia-related cardiovascular abnormalities play a 
signiﬁ  cant role in mortality in patients with CKD, and a 
number of observational studies have described a clear 
relationship between anemia and mortality in CKD patients. 
In studies performed on large populations of prevalent 
hemodialysis patients in the US, both total mortality rate and 
cardiovascular-related mortality rate were shown to increase 
along with the decrease in hematocrit (Madore et al 1997; 
Ma et al 1999; Collins et al 2001). These registry studies 
were, however, much limited by considering only a few 
number of potentially confounding covariates. This is not the 
case for the DOPPS study, which took into account a large 
number of case-mix characteristics and found signiﬁ  cantly 
lower relative risks of mortality and all-cause hospitalization 
for every 1 g/dL higher hemoglobin concentration, both in 
a European (Locatelli et al 2004) and US (Robinson et al 
2005) large sample population of hemodialysis patients. 
More recently, a systematic review of published observa-
tional studies investigating anemia and mortality in dialysis 
patients conﬁ  rmed a consistent trend towards increased 
mortality with decreasing Hb levels (Volkova and Arab 
2006). Although less consistent, recent observations indicate 
a clear association between anemia and increased mortality 
also in CKD patients who are not yet on dialysis (Kovesdy 
et al 2006; Levin et al 2006). It should, however, be borne in 
mind that most observational studies have so far considered 
only the point values of hemoglobin or hematocrit, which 
may be misleading due to the fact that many patients do not 
have stable Hb levels over time: that is the reason why some 
observational studies of patients in the conservative phase of 
CKD have used time-averaged rather than single hemoglobin 
values when analyzing their impact on patients’ survival 
(Collins et al 2001; Regidor et al 2006).
The presence of anemia during the early stages of CKD 
may also fasten the progression of kidney damage. Reduced 
oxygen delivery to the kidney caused by anemia may indeed 
lead to a progressive destruction of tubules, interstitial 
ﬁ  brosis, and increased oxidative stress, all factors which 
are expected to favor the progression of the disease (Ros-
sert et al 2002). Clinical studies support the presence of a 
positive association between higher hemoglobin levels and a 
decrease in the rate of loss of renal function (Kuriyama et al 
1997; Jungers et al 2001), and ongoing trials are investigat-
ing the possible beneﬁ  ts of correcting hemoglobin levels on 
the progression of CKD.
Clinical beneﬁ  ts of correcting renal 
anemia
The availability of recombinant human erythropoietin 
(rHuEPO) has greatly changed the management of anemia 
in patients with CKD, allowing hemoglobin levels to be 
effectively moved towards higher values. The gene encoding 
for EPO was cloned in 1985 (Lin et al 1985) and rHuEPO 
has been used in the treatment of renal anemia since 1986 
(Winearls et al 1986; Eschbach et al 1987). Since then, a num-
ber of clinical trials have documented that the administration 
of rHuEPO maintains adequate hemoglobin levels and avoids 
transfusion dependency in CKD patients. Starting from the 
clear association observed between lower hemoglobin levels 
and increased mortality in CKD patients, the availability of 
an effective therapeutic instrument to treat renal anemia soon 
raised the question as to whether correcting anemia may be 
able to improve patient outcome. Several intervention studies 
have been performed to test this hypothesis. Many of these 
studies were also aimed at verifying, through randomized 
allocation of the patients to different target hemoglobin 
levels, whether complete rather than partial correction of 
renal anemia through rHuEPO administration would lead to 
the best results in terms of survival or surrogate endpoints 
(left ventricular mass, quality of life).Therapeutics and Clinical Risk Management 2007:3(3) 435
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Patients with CKD not receiving dialysis are less likely 
to have already established cardiovascular disease, as the 
prevalence of left ventricular hypertrophy and heart disease 
progressively increases as renal function declines (Levin 
et al 1999). Therefore, it has been hypothesized that they 
may benefit more from anemia correction. Preliminary 
data from mainly small, uncontrolled studies indicated that 
anemia correction was able to lead to partial regression of 
left ventricular hypertrophy (Portoles et al 1997; Hayashi et 
al 2000; Frank et al 2004), although such an effect was not 
conﬁ  rmed in more recent studies (Roger et al 2004). How-
ever, it must be pointed out that the randomized controlled 
trial by Roger et al (2004) suffered from the relative close-
ness of the achieved hemoglobin values between the two 
randomization groups, whereas Levin et al (2005) observed 
an inverse relationship between the decrease in hemoglobin 
levels and left ventricular mass index among the patients 
whose hemoglobin decreased by 1.0 g/dL during follow-
up, regardless of the trial arm.
Besarab et al (1998) were the ﬁ  rst who tested the effect 
of hemoglobin normalization, as compared with only partial 
anemia correction, in patients on dialysis. The study, which 
considered hard outcomes such as mortality and cardiac 
events, was actually halted after 29 months because the 
trends in mortality/acute myocardial infarction in the two 
randomization arms were such that it was unlikely that any 
beneﬁ  t would be obtained from complete anemia correction. 
However, the study population consisted of hemodialysis 
patients aged more than 65 years with clinical evidence of 
congestive heart failure or ischemic heart disease, who were 
suggested to be affected by too many co-morbidities to beneﬁ  t 
from anemia normalization, and it is also possible that the 
co-existence of reduced cardiac output and vascular grafts 
in the majority (almost 70%) of the study population may 
have increased the likelihood of adverse events secondary 
to complete anemia correction, including graft thrombosis. 
Furthermore, a secondary analysis did reveal an inverse 
relationship between hematocrit values and mortality rates 
in both groups, with the patients who actually achieved a 
level of 42% showing the best survival rate, although this 
ﬁ  nding might have been due to survivor selection. Other 
studies performed in less compromised dialysis patients did 
not ﬁ  nd a signiﬁ  cant effect of complete anemia correction 
on survival, but such studies were not speciﬁ  cally designed 
to test mortality (Furuland et al 2003; Parfrey et al 2005). 
Also surrogate endpoints, such as left ventricular mass, were 
not shown to be positively affected by the achievement of 
higher hemoglobin levels through rHuEPO administration 
in dialysis patients (Foley et al 2000; Parfrey et al 2005), 
with the exception of only quality of life, which seems to be 
positively inﬂ  uenced by complete anemia correction (Moreno 
et al 2000; Furuland et al 2003; Parfrey et al 2005).
Fewer data exist on the effects of complete anemia cor-
rection on clinical outcome in CKD patients not receiving 
dialysis. The clinical trial by Rossert et al (2006) did not ﬁ  nd 
any difference in the risk of cardiovascular adverse events 
between patients randomized to different hemoglobin tar-
gets, but the study was primarily aimed at testing the effect 
of treatment on the rate of progression of CKD rather than 
on cardiovascular prognosis. Further important information 
as to this point will be provided by on-going or just ended 
clinical trials, such as the Cardiovascular Reduction Early 
Anemia Treatment Epoetin beta (CREATE) study and the 
Anemia CORrection in Diabetes (ACORD) trial, but the 
preliminary results of these studies do not seem to show 
any cardiovascular advantage in favor of complete anemia 
correction in CKD patients not yet on dialysis.
Altogether, the results of the available studies published 
so far indicate that partial correction of renal anemia by 
means of rHuEPO administration is accompanied by sig-
niﬁ  cant improvements in cardiac structure and function, 
but no further major effect on survival and left ventricular 
mass seems to be achieved by normalizing hemoglobin 
levels in patients with CKD. However, caution is warranted 
in interpreting these results, as in most cases they were 
obtained from heterogeneous studies that were not primarily 
designed to analyze mortality and were heavily conditioned 
by the relative closeness of the hemoglobin values achieved 
during follow-up between the groups of patients randomized 
to different levels of anemia correction. 
Epoetin beta and renal anemia
Clinical pharmacology
Nowadays, there are three erythropoiesis-stimulating 
agents available on the market for the treatment of renal 
anemia: epoetin alfa, epoetin beta, and darbepoetin alfa. 
Epoetin alfa and epoetin beta are both synthesized in 
Chinese hamster ovary cells and share the same amino 
acid sequence as endogenous EPO, but differences in the 
manufacturing process between the two glycoproteins 
reflect the differences in their carbohydrate moieties 
(Storring et al 1998). On the contrary, darbepoetin alfa 
is biochemically different from endogenous EPO, due 
to an additional two glycosylation chains N-linked to Therapeutics and Clinical Risk Management 2007:3(3) 436
Locatelli et al
the protein backbone of the molecule. Differences in the 
carbohydrate moieties of the rHuEPOs determine dif-
ferences in the pharmacokinetic and pharmacodynamic 
properties between these agents.
The differences in pharmacokinetic and pharmacodynamic 
properties of epoetin beta and epoetin alfa have been conﬁ  rmed 
in a randomized crossover study on healthy volunteers, in 
which the terminal elimination half-life of intravenous epoetin 
beta was found to be 20% longer than that observed with 
intravenous epoetin alfa; the half-life for epoetin beta was also 
longer with the subcutaneous route, although the difference 
did not reach statistical signiﬁ  cance (serum concentration after 
subcutaneous administration appears to be higher for epoetin 
beta than for epoetin alfa from 48 to 66 hours after dosing, 
and this reﬂ  ects delayed drug absorption with epoetin beta 
compared with epoetin alfa; in addition, epoetin beta seems 
to induce a greater absolute reticulocyte response than epoetin 
alfa after subcutaneous administration). These differences are 
most probably explained by the differences in the types and 
relative proportions of the carbohydrate side chains on the 
glycoprotein molecules present in the two preparations. 
Pharmacokinetic and pharmacodynamic responses 
to epoetin beta differ greatly according to the route of 
administration. Although peak serum concentration 
is more than 10 times greater after intravenous than 
subcutaneous administration, the terminal elimination 
half-life for epoetin beta administered via subcutane-
ous injection is almost three-fold that of the same dose 
given intravenously (Halstenson et al 1991), likely 
due to the delayed absorption following subcutaneous 
administration. Interestingly, the absolute reticulocyte 
response is greater when epoetin beta is administered 
subcutaneously rather than intravenously (Halstenson 
et al 1991), suggesting that the response to epoetin is 
not related to its peak plasma concentration but rather 
to its maintenance above a critical threshold concentra-
tion. The prolonged half-life following subcutaneous 
administration of epoetin beta suggested the possibility 
of increasing the interval between injections when using 
this route of administration, as confirmed by rHuEPO 
levels remaining within the target range for most of the 
period between injections even with once-weekly sub-
cutaneous dosing (Besarab et al 1992). In addition, dose 
requirements to maintain target hemoglobin levels are 
significantly lower when epoetin beta is administered 
subcutaneously compared with intravenously (Besarab 
et al 1992; Kaufman et al 1998). For this reason, current 
treatment guidelines (Locatelli et al 2004a) recommend 
the subcutaneous route of administration of epoetin beta 
in order to minimize treatment costs.
Efﬁ  cacy
Although the subcutaneous route of administration is cur-
rently recommended for epoetin beta, due to pharmaco-
logical and economic considerations, it can also be given 
intravenously, if necessary. The efﬁ  cacy of intravenous 
epoetin beta has actually been established in several studies 
in patients with CKD, either pre-dialysis or on hemodialysis 
(Kaupe et al 1990; Abraham and Macres 1991; Bennett 
1991; Kaizu et al 1993; Sinnassamy et al 1993; Bommer 
et al 1998).
Nonetheless, the sustained duration of action described 
in pharmacokinetic studies supports the use of subcutaneous 
epoetin beta, administered once weekly, at least in the main-
tenance phase of renal anemia treatment. In fact, although 
traditionally rHuEPO was administered three times weekly, 
studies evaluating less frequent administration regimens have 
demonstrated that once-weekly subcutaneous administration 
of epoetin beta during the maintenance phase of therapy has 
the same efﬁ  cacy in maintaining Hb levels as the three-times-
weekly regimen. In particular, two large-scale, randomized, 
controlled studies (Weiss et al 2000; Locatelli et al 2002) 
showed that stable Hb levels could be maintained with once-
weekly epoetin beta treatment without an increase in dose 
compared with administration two or three times weekly. 
Weiss et al (2000) conducted an open label, randomized, con-
trolled, parallel-group study designed to detect no difference 
in efﬁ  cacy between once-weekly and two- or three-times-
weekly subcutaneous epoetin beta treatment in 158 patients 
on hemodialysis. Patients with Hb levels maintained between 
10 and 12.5 g/dL during an 8-week pre-treatment period with 
subcutaneous epoetin beta two or three times weekly were 
randomized either to receive once weekly subcutaneous epo-
etin beta treatment or to remain on their original regimen for 
24 weeks. No signiﬁ  cant differences were observed in Hb 
levels and in weekly epoetin beta dose between the treatment 
regimens. The study by Locatelli et al (2002) was designed to 
demonstrate therapeutic and statistical equivalence between 
once-weekly and three-times-weekly subcutaneous epoetin 
beta treatment in stable patients on hemodialysis. This was 
an open-label, randomized, parallel-group study conducted 
over a 24-week period: 173 patients on hemodialysis were 
randomized to treatment with once- or three-times-weekly 
epoetin beta. Mean hematocrit levels remained stable Therapeutics and Clinical Risk Management 2007:3(3) 437
Epoetin beta and renal anemia
throughout the study and the mean weekly epoetin beta dose 
was not different in the two treatment groups. 
Several small-scale studies have investigated the use of 
once-weekly subcutaneous epoetin also in patients on perito-
neal dialysis (Lui et al 1991; Saleh et al 1991; Nomato et al 
1994; Frifelt et al 1996), suggesting that a maintenance dose 
of subcutaneous epoetin is effective when given once weekly 
in these patients. For example, a prospective, randomized 
study compared the dosage requirements of subcutaneous 
epoetin beta administered either once weekly or three times 
weekly in 39 patients on peritoneal dialysis previously 
stabilized on epoetin beta three times weekly (Frifelt et al 
1996). At the endpoint there was no difference in hemoglobin 
levels between treatment regimens, and over the 3-month 
study period the average dose of epoetin beta was slightly 
lower for patients receiving once-weekly compared with 
three-times-weekly treatment. More recently, another study 
investigated whether epoetin beta administered once weekly 
was effective at maintaining hemoglobin levels in patients 
on peritoneal dialysis previously stabilized on epoetin two 
or three times weekly and whether once every two weeks 
administration was effective in patients previously stabilized 
on a once-weekly regimen (Grzeszczak et al 2005). In both 
cases, over the 6-month study period, the patients were able 
to maintain hemoglobin levels within the target range without 
a signiﬁ  cant increase in overall weekly dose compared with 
their respective previous regimen. 
As well as being effective in patients on dialysis, subcuta-
neous epoetin beta is effective in correcting renal anemia also 
in patients with CKD who do not require renal replacement 
therapy (Koch et al 1995). An open-label, multicenter study 
including 84 pre-dialysis patients suggested that once-weekly 
subcutaneous epoetin beta is as effective as more frequent 
administration in maintaining hemoglobin levels in CKD 
patients in the conservative phase (Albetazzi et al 1998). 
Safety and tolerability
More than a decade of experience with epoetin beta has 
demonstrated its favorable safety and tolerability proﬁ  le 
in patients with CKD. During its clinical trial program, no 
long-term trend or distinct pattern in adverse events was 
identiﬁ  ed (F. Hoffmann-La Roche, data on ﬁ  le). As with other 
erythropoiesis-stimulating agents (ESA), the most common 
adverse event is hypertension. A number of pathophysiologi-
cal mechanisms have been postulated to explain the rise in 
blood pressure values observed after ESA administration. The 
increase in blood viscosity secondary to anemia correction 
appears as the most obvious one. This is particularly true 
when anemia correction is achieved too rapidly or higher 
hemoglobin targets are reached. However, often blood pres-
sure changes are not clearly related to achieved hemoglobin 
levels. Enhanced vascular reactivity and vasoconstrictor 
responses have been thus suggested to play a role. Given 
that ESA-induced hypertension seems to be dose-related, it is 
possible that switching patients from intravenous to subcuta-
neous epoetin therapy, by allowing lower doses, may reduce 
the incidence of adverse events, above all hypertension. This 
is suggested by the results of a study on hypertensive hemo-
dialysis patients under intravenous epoetin therapy, whose 
pre-dialysis blood pressure levels signiﬁ  cantly decreased 
after switching to subcutaneous administration, so that within 
6 months nearly half of them were no longer considered 
hypertensive (Navarro et al 1995). A larger study of 406 
patients receiving maintenance intravenous or subcutane-
ous epoetin treatment who were switched to subcutaneous 
epoetin beta showed epoetin beta to be well tolerated and 
effective, with adverse events occurring at a very low rate 
during the study (Kleophas et al 2003). Finally, different 
studies reported that once-weekly subcutaneous epoetin beta 
is as well tolerated as two- or three-times-weekly regimens 
(Weiss et al 2000; Locatelli et al 2002). It must also be con-
sidered that the reduced dosage requirements when epoetin 
is administered subcutaneously compared with intravenously 
may allow substantial cost savings, without compromising ef-
fectiveness or safety of therapy (Kaufman et al 1998; Besarab 
et al 2002; Hynes et al 2002).
Antibody-mediated pure red cell aplasia (PRCA) is a rare 
complication following therapy with ESA. Between 1998 and 
2002, an upsurge of PRCA cases have been described, but this 
was mainly related to treatment with epoetin alfa (Casadevall 
et al 2002; Bennett et al 2004). Reports of PRCA with epoetin 
beta have been sporadic and limited (Locatelli et al 2004b).
Conclusions
Anemia is a frequent and early complication of CKD and is 
associated with adverse cardiovascular outcomes and poor 
patient survival. Renal anemia can be effectively managed 
by the administration of rHuEPO, which is able to increase 
hemoglobin levels and has been associated with signiﬁ  cant 
improvements in the cardiovascular status of patients with 
CKD. Epoetin beta represents one of the three erythropoi-
esis-stimulating agents available on the market for the treat-
ment of renal anemia. The increased effectiveness and the 
longer half-life shown by epoetin beta when administered Therapeutics and Clinical Risk Management 2007:3(3) 438
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subcutaneously, as compared with intravenously, make the 
subcutaneous route of administration the one recommended 
by current best practice guidelines, allowing target hemoglo-
bin levels to be maintained at a lower epoetin dose and lower 
frequency of administration. 
The ability to administer epoetin beta once weekly is as-
sociated with several additional beneﬁ  ts. Reducing adminis-
tration frequency from three times weekly to once weekly is 
likely to improve patients’ acceptance of epoetin treatment, 
potentially encouraging self-administration and improving 
compliance. The once-weekly schedule contributes also to 
the reduction of treatment costs and nursing time required 
for optimal anemia management.
In conclusion, the proven efﬁ  cacy and safety proﬁ  le of 
epoetin beta, combined with the increased convenience of 
less frequent dosing, make epoetin beta a safe and effective 
treatment option that can help more patients to reach their 
therapeutic targets in the management of renal anemia.
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